Pharmacokinetics, safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1 (IMPAACT P1093): results of an open-label, phase 1–2 trial
Authors:
Open Access
- 27 April 2022
- journal article
- research article
- Published by Elsevier in The Lancet HIV
- Vol. 9 (5) , e332-e340
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trialThe Lancet HIV, 2020
- Safety, Pharmacokinetics and Efficacy of Dolutegravir in Treatment-experienced HIV-1 Infected AdolescentsThe Pediatric Infectious Disease Journal, 2015
- A sensitive HPLC–MS/MS method for the determination of dolutegravir in human plasmaJournal of Chromatography B, 2014
- Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING studyThe Lancet, 2013
- Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 studyThe Lancet, 2013
- Effect of Food on the Pharmacokinetics of the Integrase Inhibitor DolutegravirAntimicrobial Agents and Chemotherapy, 2012
- Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trialThe Lancet Infectious Diseases, 2012
- Virologic Response to Potent Antiretroviral Therapy and Modeling of HIV Dynamics in Early Pediatric InfectionThe Journal of Infectious Diseases, 2007
- Range of Normal Neutrophil Counts in Healthy Zimbabwean InfantsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2006
- Developmental Pharmacology — Drug Disposition, Action, and Therapy in Infants and ChildrenNew England Journal of Medicine, 2003